Why the study?
Does percutaneous coronary intervention reduce cardiac death compared with optimal medical therapy as an initial treatment strategy in patients with coronary chronic total occlusion?
Does percutaneous coronary intervention reduce cardiac death compared with optimal medical therapy as an initial treatment strategy in patients with coronary chronic total occlusion?
In patients with coronary chronic total occlusion, an initial strategy of percutaneous coronary intervention did not significantly reduce the risk of cardiac death compared with optimal medical therapy alone.
Initial PCI was not associated with lower cardiac death than OMT in CTO; leaves open whether RCTs would demonstrate benefit.
BACKGROUND: Limited data are available on the long-term clinical outcomes of coronary chronic total occlusion (CTO) patients who receive optimal medical therapy (OMT) compared with percutaneous coronary intervention (PCI). METHODS AND RESULTS: Between March 2003 and February 2012, 2,024 patients with CTO were enrolled in a single-center registry. Among this patient group, we excluded CTO patients who underwent coronary artery bypass grafting and classified patients into the OMT group (n=664) or PCI group (n=883) according to initial treatment strategy. Propensity-score matching was also performed. The primary outcome was cardiac death. The median follow-up duration was 45.8 (interquartile range: 22.8-71.1) months. In the PCI group, 699 patients (79.2%) underwent successful revascularization. In the propensity-score matched population (533 pairs), there was no significant difference in the rate of cardiac death between the OMT and PCI groups (hazard ratio, 1.57; 95% confidence interval, 0.91-2.72, P=0.11). In the subgroup analysis, there were no significant interactions between the PCI strategy and cardiac death among several subgroups except that regarding collateral flow grades 0-2 vs. those with grade 3 (P=0.01). CONCLUSIONS: As an initial treatment strategy, PCI did not reduce cardiac death compared with OMT for the treatment of CTO in the drug-eluting stent era.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: